Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
November 10, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage...
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
October 26, 2022 08:04 ET
|
Unicycive Therapeutics, Inc.
Multiple Data Presentations Support the Company’s Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease Independently Hosted Key...
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
September 29, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
September 07, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA...
Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 24, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Second Quarter Financial Results and Provides Business Update
August 15, 2022 18:03 ET
|
Unicycive Therapeutics, Inc.
On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
July 26, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...
Unicycive Reports Key Findings from Market Research with Nephrologists
July 20, 2022 07:12 ET
|
Unicycive Therapeutics, Inc.
Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...
Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
July 18, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties...